Literature DB >> 17803738

Pharmacokinetics of oxytetracycline in the American horseshoe crab, Limulus polyphemus.

M W Nolan1, S A Smith, D Jones.   

Abstract

The American horseshoe crab, Limulus polyphemus, is regularly cultured and maintained in research laboratories and public aquaria. Rising concerns over the health of these captive animals makes the diagnosis and treatment of pathological conditions in L. polyphemus essential. This study investigated the kinetics of oxytetracyline following either intravascular or oral dosing. Oxytetracylcine is a broad-spectrum antibiotic used in the treatment of various bacterial diseases of aquatic animals. A noncompartmental model was developed to describe the pharmacokinetics of oxytetracycline (OTC) in the horseshoe crab. The following parameters were determined for a single intravascular bolus of 25 mg/kg OTC: AUC = 9524.60 microg.h/mL, MRT = 443.65 h, Clb = 0.044 mL/min/kg, Vd(ss) = 1.164 L/kg, t(1/2) = 128.3 h, Cmax = 55.90 microg/mL, C(ave) = 27.39 microg/mL. Following a single oral bolus of 25 mg/kg, these parameters were calculated: AUC = 5861.81 microg.h/mL, MRT = 395.89 h, Clb = 0.071 mL/min/kg, Vd(ss) = 1.688 L/kg, t(1/2) = 210.0 h, Cmax = 7.83 microg/mL, C(ave) = 2.89 microg/mL, F = 61.56%.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17803738     DOI: 10.1111/j.1365-2885.2007.00891.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  2 in total

Review 1.  Microarray analyses of shrimp immune responses.

Authors:  Takashi Aoki; Han-Ching Wang; Sasimanas Unajak; Mudjekeewis D Santos; Hidehiro Kondo; Ikuo Hirono
Journal:  Mar Biotechnol (NY)       Date:  2011-08       Impact factor: 3.619

2.  Comparative pharmacokinetics of oxytetracycline in blunt-snout bream (Megalobrama amblycephala) with single and multiple-dose oral administration.

Authors:  Ru-Qin Li; Yu-Wei Ren; Jing Li; Can Huang; Jun-Hui Shao; Xiao-Xuan Chen; Zhi-Xin Wu
Journal:  Fish Physiol Biochem       Date:  2015-03-31       Impact factor: 2.794

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.